Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 11, 2020
[ Tue, Feb 11th 2020
] - WOPRAI
[ Tue, Feb 11th 2020
] - WOPRAI
[ Tue, Feb 11th 2020
] - WOPRAI
[ Tue, Feb 11th 2020
] - WOPRAI
[ Tue, Feb 11th 2020
] - WOPRAI
[ Tue, Feb 11th 2020
] - WOPRAI
[ Tue, Feb 11th 2020
] - WOPRAI
[ Tue, Feb 11th 2020
] - WOPRAI
[ Tue, Feb 11th 2020
] - WOPRAI
[ Tue, Feb 11th 2020
] - WOPRAI
Mon, February 10, 2020
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
Navin Jacob Maintained (ABBV) at Strong Buy with Increased Target to $105 on, Feb 10th, 2020
Navin Jacob of UBS, Maintained "AbbVie Inc." (ABBV) at Strong Buy with Increased Target from $96 to $105 on, Feb 10th, 2020.
Navin has made no other calls on ABBV in the last 4 months.
There are 3 other peers that have a rating on ABBV. Out of the 3 peers that are also analyzing ABBV, 0 agree with Navin's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Navin
- Steve Scala of "TD Cowen" Reiterated at Buy with Increased Target to $98 on, Thursday, December 26th, 2019
- Andrew Baum of "Citigroup" Maintained at Strong Buy with Increased Target to $98 on, Wednesday, November 20th, 2019
- Marc Goodman of "UBS" Maintained at Strong Buy with Increased Target to $96 on, Tuesday, November 19th, 2019
